Erdafitinib is primarily used in the treatment of advanced or metastatic urothelial carcinoma, particularly in patients who have susceptible FGFR2 or FGFR3 genetic alterations. It is prescribed when the cancer has progressed during or after platinum-containing chemotherapy. As a selective tyrosine kinase inhibitor, it targets fibroblast growth factor receptors (FGFRs), blocking signaling pathways that promote tumor growth and survival. Its application represents a precision medicine approach, where therapy is tailored based on the tumor’s genetic profile. Erdafitinib has shown clinical benefit in improving response rates and disease control in biomarker-selected patients, making it a valuable option in oncology for FGFR-driven cancers.